Navigation Links
BELLUS Health reports results for the fourth quarter of 2008
Date:2/26/2009

tainty, including, but not limited to, the estimated amounts to be recovered, the yield of the substitute financial instruments and the timing of future cash flows, and the market for these types of instruments. The resolution of these uncertainties could be such that the ultimate fair value of these investments may vary significantly from the Company's current estimate. Changes in the near term could require significant changes in the recognized amount of these assets. As the Company records the New notes at current fair value each period, such adjustments will directly impact earnings.

As at December 31, 2008, the Company's workforce comprised 104 employees compared to 172 employees as at December 31, 2007. During the third quarter of 2008, the Company reduced further its research activities and associated workforce to focus on its key projects.

As at January 31, 2009, the Company had 50,043,892 common shares outstanding, 220,000 common shares issuable to the Chief Executive Officer upon the achievement of specified performance targets, 4,649,008 options granted under the stock option plan, 2,884,471 shares potentially issuable under the convertible notes (subject to adjustments, refer to note 11 to the consolidated financial statements) and 2,250,645 warrants outstanding (subject to adjustments in certain circumstances).

Change in functional and reporting currency

Effective July 1, 2007, the Company adopted the US dollar as its functional and reporting currency, as a significant portion of its revenues, expenses, assets, liabilities and financing are denominated in US dollars. Prior to that date, the Company's operations were measured in Canadian dollars and the consolidated financial statements were expressed in Canadian dollars. The Company followed the recommendations of the Emerging Issues Committee (EIC) of the Canadian Institute of Chartered Accountants (CICA), set out in EIC-130, "Translation method when th
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. , The study finds ...
(Date:7/29/2014)... By Dennis Thompson ... -- Exercise, a healthy diet and good sleep can protect ... down the aging process at a cellular level, researchers report. ... stressful events are linked to increased shortening of telomeres, the ... quickly cells age. "We found that over a one-year ...
(Date:7/29/2014)... 2014 During his 37 years in dental ... Associates, has had a steady stream of college students shadow ... have now gone on to dental school and some are ... shadowing program helps college students find success. , For students ... them the chance to see a realistic view of what ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Boise, Idaho (PRWEB) July 29, 2014 ... & Hart LLP ’s Boise office, has been appointed ... Cross of Greater Idaho. , Busacker is an experienced ... executive compensation matters. He advises clients on a wide ... plan design, plan administration, compliance, and governance concerns. His ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... (cell culture) research currently underway at the Peninsula Medical School ... and develop therapies for the treatment of multiple tumours in ... a protein called merlin, which in turn cause cancers in ... brain. Schwann cells produce the sheaths that surround and insulate ...
... Makes First Investment in Antibacterial Therapeutics From ... its Biodefense and Pandemic ... today,announced the close of a $30 million Series B financing ... now completing Phase I testing. The financing was led by ...
... Group Calls for Funding Suspension After Trial ... a Baltimore Sun,opinion piece today ( http://www.baltimoresun.com/news/opinion/oped/bal ... suspension of costly HIV vaccine research funding ... proven HIV/AIDS prevention,testing and treatment strategies., ...
... take their lives in the spring, doctors say , , SUNDAY, March ... time of renewal and hope, the greatest number of suicides in ... the American College of Emergency Physicians. , It,s not clear why ... L. Lawrence. But "we do know that suicide is the 11th ...
... Music therapy can help reduce anxiety and improve physical ... everyone has used music at one time or another ... discipline of music therapy takes the use of music ... "Music therapy is an evidence-based practice that can affect ...
... YORK, March 21 Americans with ... their Medicare Advantage Plan have an ... to this report from UnitedHealthcare at:, ... access video, audio, text, graphics and,photos ...
Cached Medicine News:Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Music as Medicine 2Health News:Music as Medicine 3
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... that cause serious infections and diseases, announced today that ... Company,s stock, the NYSE MKT (the "Exchange") has contacted ... Company stated that its policy is not to comment ... Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... Report from Trial of Quadramet in Combination with Velcade for ... 11 Quadramet (153 Samarium-lexidronam) is ... and is used to treat pain caused by cancer that ... (bortezomib) is approved for the treatment of ...
... 10 Endo Pharmaceuticals (Nasdaq: ENDP ) ... agreements to develop novel treatments for pain and to ... with Harvard University , is based upon a ... Harvard Medical School,s Richard J. Kitz Professor of Anaesthesia ...
Cached Medicine Technology:Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 3
Bi-phasic peristaltic infusion pump for tumescent work....
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
... represents a major advance in the ... procedures. Combined with precision fluid management, ... solid grooved probe design and patented ... been designed to minimize trauma to ...
Inquire...
Medicine Products: